Health Technology Takeda Pharmaceutical Co., Ltd. Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2022
JPY USD Revenue 3,569.00B 31,760.44M Gross Profit 2,043.63B 18,186.20M Operating income 610,496M 5,432.77M Income before tax 317,938M 2,829.31M Net income 230,059M 2,047.28M EBITDA 1,193.64B 10,622.21M Diluted EPS 145.86 1.29 Dividends Per Share 180 1.60 Total Assets 13,178.01B 108,572.75M Total liabilities 7,494.49B 61,746.62M Total equity 5,683.01B 46,821.99M Operating cash flow 1,021.21B 9,087.77M Currency in JPY Currency in USD
Historical Data Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
1,770.53B
2,097.22B
3,291.18B
3,197.81B
3,569.00B
Gross Profit
1,148.86B
1,275.55B
1,789.37B
1,798.37B
2,043.63B
Operating income
195,320M
218,686M
302,612M
447,610M
610,496M
Income before tax
217,205M
127,612M
-60,754M
366,159M
317,938M
Net income
186,886M
135,192M
44,241M
376,005M
230,059M
EBITDA
377,447M
466,377M
886,261M
1,007.28B
1,193.64B
Diluted EPS
237.55
139.82
28.24
238.95
145.86
Dividends Per Share
180
180
180
180
180
Total Assets
4,106.46B
13,792.77B
12,821.09B
12,912.29B
13,178.01B
Total liabilities
2,089.05B
8,606.78B
8,093.60B
7,735.11B
7,494.49B
Total equity
1,997.42B
5,181.98B
4,723.48B
5,173.03B
5,683.01B
Operating cash flow
379,600M
302,609M
555,410M
905,073M
1,021.21B
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
15,974.84M
18,911.85M
30,270.54M
30,151.70M
31,760.44M
Gross Profit
10,365.80M
11,502.42M
16,457.72M
16,956.61M
18,186.20M
Operating income
1,762.30M
1,972.01M
2,783.25M
4,220.44M
5,432.77M
Income before tax
1,959.76M
1,150.74M
-558.78M
3,452.46M
2,829.31M
Net income
1,686.20M
1,219.10M
406.90M
3,545.29M
2,047.28M
EBITDA
3,405.56M
4,205.58M
8,151.34M
9,497.50M
10,622.21M
Diluted EPS
2.14
1.26
0.25
2.25
1.29
Dividends Per Share
1.62
1.62
1.65
1.69
1.60
Total Assets
38,612.71M
124,612.85M
118,763.31M
116,853.33M
108,572.75M
Total liabilities
19,643.19M
77,759.25M
74,972.05M
70,001.05M
61,746.62M
Total equity
18,781.60M
46,817.41M
43,754.18M
46,814.81M
46,821.99M
Operating cash flow
3,424.99M
2,728.79M
5,108.35M
8,533.80M
9,087.77M
Valuation Measures
Mar 2022
PER 23.77 ROA 1.76% ROE 4.23% Operating margin 17.10% Profit margin 6.44%
Key executives
President, CEO & Representative Director:
Christophe Weber
Chief Financial Officer & Director:
Constantine Saroukos
Director, President-Research & Development:
Andrew S. Plump
Chief Medical & Scientific Officer:
Michael E. Mendelsohn
Chief Accounting Officer & Corporate Controller:
Norimasa Takeda Shareholders
Nomura Asset Management Co., Ltd. (4.2%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
BlackRock Fund Advisors (3.2%)
The Vanguard Group, Inc. (2.5%)
Nikko Asset Management Co., Ltd. (2.0%)
Daiwa Asset Management Co. Ltd. (1.9%)
Nippon Life Insurance Co. (1.8%)
Norges Bank Investment Management (1.4%)
BlackRock Japan Co., Ltd. (1.4%)
Takeda Pharmaceutical Co., Ltd. (1.3%)
Related Companies
Takeda Pharmaceutical Co. Ltd. /Life Science Park Ops/
Takeda Pharmaceutical Co Ltd /Asker Pharma Manufacturing Ops/
Takeda Digital Ventures
Takeda Pharmaceutical Co. Ltd. /5 Prescription Pharma Asset/
Takeda Pharmaceutical Employee Long Term Incentive Plan
Takeda Pharmaceutical Co. Ltd. /Prescription Pharma Ass
Takeda Dunboyne Biologics Ltd.
Plasmaspendedienst GmbH
Takeda Belgium NV
Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
Takeda Re Insurance AG
Plasmapunkt Favoriten GmbH
Takeda Malaysia Sdn. Bhd.
Takeda Pharmaceutical Co. Ltd. /Latam Bus/
Takeda Oranienburg Real Estate GmbH & Co. KG
Pvp Biologics, Inc.
Maverick Therapeutics, Inc.
Gammadelta Therapeutics Ltd.
Takeda Pharmaceutical Director Incentive Plan
Takeda Pharmaceutical Employee Incentive Plan
Oy Leiras Takeda Pharmaceuticals AB
Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
Takeda Pharma AB
Takeda Development Center Americas, Inc.
Takeda Ukraine LLC
Takeda Pharmaceuticals Taiwan Ltd.
Takeda SRL
Takeda Hellas SA
Takeda Christiaens SCA/CVA
Takeda Belgium SCA/CVA
Competitors
AstraZeneca PLC
Grifols, S.A. Class A
Green Cross Corporation
Amgen Inc.
CSL Limited
Karyopharm Therapeutics, Inc.
Amicus Therapeutics, Inc.
Protalix Biotherapeutics, Inc.
ADMA Biologics, Inc.
Novartis AG
Pfizer Inc.
Johnson & Johnson
Sanofi
Mochida Pharmaceutical Co., Ltd.
AbbVie, Inc.
Merck & Co., Inc.
Organon & Co.
Roche Holding Ltd Dividend Right Cert.
Bristol-Myers Squibb Company
Bayer AG
Novo Nordisk A/S Class B
UCB S.A.
Merck KGaA
Swedish Orphan Biovitrum AB
JCR Pharmaceuticals Co., Ltd.
Supernus Pharmaceuticals, Inc.
Pharming Group NV
Oncopeptides AB
BioCryst Pharmaceuticals, Inc.
ISU Abxis Co., Ltd.
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 27 Jan, 2023
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close